Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

Table 3 Self-reported psychological well-being, subjective cognitive complaints, depressive symptoms and level of fatigue

	Patients VEGFR TKI		Patient controls		Healthy controls
	*Mean*	SD	Mean	SD	Mean	SD
SCL-90-R
Anxiety	13.07**	3.10	12.75*	3.06	11.10	1.71
Depression	23.87***	6.31	22.55**	5.32	18.20	2.68
Sleep disturbance	4.93	2.57	5.00	2.03	4.10	1.40
Agoraphobia	7.90	2.01	8.10	2.20	7.40	0.77
Somatization	19.23***	5.73	17.40*	6.07	14.17	3.18
Cognitive-performance difficulty	14.77**	4.68	14.75**	4.82	11.43	2.13
Interpersonal sensitivity and paranoid ideation	20.90	3.63	22.50	5.69	20.87	3.15
Anger-hostility	6.90	1.27	6.90	1.12	6.43	0.86
Total score	123.10***	24.13	121.80**	26.81	103.67	11.88
CFQ
Total score	93.37	13.20	89.55	10.13	91.80	9.64
BDI-II
Total score	9.87***	5.76	8.25**	5.78	3.60	2.98
CIS20r
Total score	67.67***	26.75	61.05*	21.11	46.60	16.24

Self-reported psychological well-being, subjective cognitive complaints, depressive symptoms and level of fatigue (mean + SD) for the patients using VEGFR TKI, the patient controls and the healthy controls. Post-hoc t-tests, patient groups compared to healthy controls: *P < 0.05, **P < 0.01, ***P < 0.001. Abbreviations: SCL-90-R Symptom Checklist-Revised, CFQ Cognitive Failures Questionnaire, BDI-II Beck Depression Inventory-Second Edition, CIS-20-R Checklist Individual Strength-Revised.

ISSN: 1471-2407